Sign In
Buy GLUE
$16.52
-6.16 (-27.16%)
At Close: Jul 31, 2026
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade
10:56am, Wednesday, 30'th Oct 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Monte Rosa Therapeutics (GLUE). While the effectiveness of this highly sought-after metric is question
This Biotech Stock Has Doubled Its Value Today—Here's Why
03:06pm, Monday, 28'th Oct 2024
Shares of Monte Rosa Therapeutics (GLUE) more than doubled Monday after the biotechnology company struck an exclusive development and commercialization license agreement with Novartis (NVS) for its tr
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
02:10pm, Monday, 28'th Oct 2024
Monte Rosa Therapeutics shares doubled Monday on a deal with Novartis to develop treatments for immune system conditions.
Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is e
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
07:00am, Monday, 19'th Aug 2024
MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases Init
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
09:17am, Thursday, 08'th Aug 2024
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.71 per share a year ago.
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Thursday, 08'th Aug 2024
IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phase 1 SAD/MAD study this summer with initial clinical
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
08:36am, Monday, 08'th Jul 2024
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
07:00am, Thursday, 27'th Jun 2024
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; f
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Monte Rosa Therapeutics Announces Leadership Team Promotions
07:00am, Thursday, 30'th May 2024
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today anno
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
07:00am, Thursday, 30'th May 2024
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today anno
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated ge
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
07:00am, Thursday, 16'th May 2024
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based me
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:01pm, Wednesday, 15'th May 2024
BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based me
